Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax (Fluticasone Propionate Inhalation Powder) Administered Twice Daily compared with Placebo in Adolescent and Adult Subjects with Severe Persistent Asthma Uncontrolled on High dose Inhaled Corticosteroid Therapy

Next Previous
X
Search
Trial Profile

A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax (Fluticasone Propionate Inhalation Powder) Administered Twice Daily compared with Placebo in Adolescent and Adult Subjects with Severe Persistent Asthma Uncontrolled on High dose Inhaled Corticosteroid Therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluticasone propionate (Primary) ; Salbutamol
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Teva Branded Pharmaceutical Products R&D

    • Most Recent Events

    • 01 Aug 2017 Results published in the Journal of Asthma
    • 31 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Aug 2013 Planned End Date changed from 1 Jul 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top